Novavax Inc
NASDAQ:NVAX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.43
10.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Novavax Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Novavax Inc
NASDAQ:NVAX
|
1.1B USD |
39%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
33%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
170.6B USD |
34%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
148.3B USD |
39%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
39%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
73.7B USD |
28%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88B AUD |
26%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
55.1B USD |
8%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
47B EUR |
22%
|
Novavax Inc
Glance View
Nestled at the intersection of innovation and dedication, Novavax Inc. emerged as a pivotal player in the biopharmaceutical landscape. Founded in 1987, the company was initially envisioned to be a biotechnology firm focused on life-saving vaccines, a mission that would increasingly align with global needs. Through diligent research and development, Novavax adopted a recombinant nanoparticle technology platform, enabling the company to develop distinctive vaccines. Using proprietary adjuvants to bolster immune responses, their work is characterized by precision and high efficacy. Novavax’s journey gained substantial momentum during the COVID-19 pandemic, as the urgent demand for vaccines spotlighted their potential. The development of their COVID-19 vaccine candidate, leveraging this cutting-edge technology, became a critical milestone, underscoring their adaptability and competence in addressing modern health challenges. From a business perspective, Novavax crafts its success by guiding innovative vaccine candidates through rigorous stages of clinical trials and regulatory approvals, ultimately leading to revenue generation via licensing agreements and government contracts. They meticulously balance risk and opportunity by targeting a spectrum of infectious diseases, aiming to broaden their product pipeline and thus capture larger market shares. Revenue flows primarily from the sale of these vaccines, which are distributed worldwide, and the company continues to explore partnerships and collaborations to enhance its market reach. Novavax showcases resilience and forward-thinking strategies, underpinned by a commitment to expanding access to essential vaccines globally, thereby meeting both public health needs and corporate growth objectives.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Novavax Inc's most recent financial statements, the company has Operating Margin of 39.2%.